Cambridge Innovation Capital
Cambridge Innovation Capital (“CIC”) was launched with initial funding from long-term institutional and strategic investors including Invesco Perpetual, Lansdowne Partners and the University of Cambridge Endowment Fund. We invest in high-growth life science and technology companies arising from the University of Cambridge and the wider Cambridge Cluster. With our close ties to the University, active angel groups and the entrepreneurial community, our mission is to be one of the leading venture capital investors in the vibrant Cambridge Cluster. Where needed, our investment strategy backed by our permanent capital structure, allows us to provide long-term financial support to our portfolio companies.
Cancer Research Technology
Cancer Research Technology Limited (CRT) is a specialist commercialisation and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is wholly owned by Cancer Research UK, the world’s leading cancer charity dedicated to saving lives through research.
IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.
Group holdings in portfolio companies reflect the undiluted beneficial equity interest excluding debt, unless otherwise explicitly stated.
For more information, please visit our website at www.ipgroupplc.com.
Johnson & Johnson Innovation
Johnson & Johnson Innovation – JJDC, Inc. is the venture capital subsidiary of Johnson & Johnson that has been investing since 1973 in the medical device, diagnostic, pharmaceutical, and consumer health areas. JJDC’s goal is to create opportunities that meet the strategic needs of its operating affiliates while providing visibility to innovative emerging technology, businesses and business models JJDC invests in companies across the continuum from early stage seed investments to the advanced stages of series venture management.
RT Partners are a boutique investment firm focused on UK IP-rich technology, with a particular emphasis on bio-tech and genomics.
We invest in seed, Series A/B, and growth stage UK technology companies.
Working with our Asian partners, we seek to help our portfolio companies in Asia.
Schroder UK Public Private Trust Plc
Schroder UK Public Private Trust Plc is an investment trust which invests in publically listed and private companies which showcase the best in British innovation. Managed by Tim Creed and Ben Wicks, the Trust utilises dedicated public and private portfolio management teams to invest with the aim of creating long-term value for its shareholders.
NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Ft. Myers and Tampa, Florida; Aliso Viejo, Carlsbad, Fresno and San Diego, California; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and CAP accredited laboratories in Rolle, Switzerland, and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.
Farallon Capital Management
Farallon is driven by its commitment to deliver superior risk-adjusted returns to its investors. Our people, our values and an investment process continually refined over 30 years are what make Farallon what it is today.
The Firm seeks to generate superior risk-adjusted returns through idiosyncratic, catalyst-driven investing with a focus on complex and niche opportunities in the Public and Private space.
Janus Henderson is a global asset manager with more than 345 investment professionals and expertise across all major asset classes. Our individual, intermediary and institutional clients span the globe and entrust us with more than US$401.6bn of their assets*. Our commitment to active management offers clients the opportunity to outperform passive strategies over the course of market cycles. Through times of both market calm and growing uncertainty, our managers apply their experience weighing risk versus reward potential – seeking to ensure clients are on the right side of change.